Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): A multicenter, phase II trial

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 1, 2009, Pages 115-122

  Boscaro, M ^a   Ludlam, W H ^b   Atkinson, B ^c   Glusman, J E ^d   Petersenn, S ^e   Reincke, M ^f   Snyder, P ^g   Tabarin, A ^h   Biller, B M K ⁱ   Findling, J ^j   Melmed, S ^k   Darby, C H ^d   Hu, K ^d   Wang, Y ^d   Freda, P U ^l   Grossman, A B ^m   Frohman, L A ⁿ   Bertherat, Jérôme ^o  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b SWEDISH MEDICAL CENTER   (United States)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j Midwest Endocrinology Associates   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

^l Och Spine at New York Presbyterian Hospitals   (United States)

^m ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^o UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; METFORMIN; PASIREOTIDE; REPAGLINIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CUSHING DISEASE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; EAR DISEASE; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERGLYCEMIA; HYPOTENSION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INNER EAR DISEASE; LIVER FUNCTION TEST; MALE; MEDIASTINUM DISEASE; MORNING DOSAGE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; STEADY STATE; THORAX DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 58149383820     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1008     Document Type: Article

References (26)

1. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M 2008 Treatment of ACTH-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454-2462
2. Emery MN, Leontiou C, Bonner SE, Merulli C, Nanzer AM, Musat M, Galloway M, Powell M, Nikookam K, Korbonits M, Grossman AB 2006 PPAR-γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-γ receptor. Clin Endocrinol (Oxf) 65:389-395
3. Heaney AP, Fernando M, Yong WH, Melmed S 2002 Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8:1281-1287
4. Heaney AP, Fernando M, Melmed S 2003 PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111:1381-1388
5. Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB 2006 The PPAR-γ activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin Endocrinol (Oxf) 64:519-522
6. Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J 2007 Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab 92:1758-1763
7. Pecori GF, Scaroni C, Arvat E, Martin M, Giordano R, Albiger N, Leao AA, Picu A, Mantero F, Cavagnini F 2006 Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf) 64:219-224
8. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E 2006 Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 147:4438-4444
9. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462
10. Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G 1990 Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary- adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 13:257-261
11. Invitti C, De Martin M, Brunani A, Piolini M, Cavagnini F 1990 Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin). Clin Endocrinol (Oxf) 32:275-281
12. Lamberts SW, Uitterlinden P, Klijn JM 1989 The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 120:760-766
13. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
14. Schmid HA, Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1):47-50
15. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482-4488
16. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, Melmed S 2004 The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 89:3027-3032
17. Van Der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ 2005 Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumour cells. Am J Physiol Endocrinol Metab 289:E278-E287
18. Hofland LJ, Van Der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654
19. Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA 2005 Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 153:R7-R10
20. Schmid HA 2008 Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69-74
21. Karnofsky DA, Burchenal JH 1949 The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 196-205
22. Simon R 1989 Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
23. Orth DN 1995 Cushing's syndrome. N Engl J Med 332:791-803
24. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M 2003 Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593-5602
25. Atkinson AB, Kennedy AL, Carson DJ, Hadden DR, Weaver JA, Sheridan B 1985 Five cases of cyclical Cushing's syndrome. Br Med J (Clin Res Ed) 291:1453-1457
26. Cozzi R, Attanasio R 2007 Octreotide for acromegaly. Expert Rev Endocrinol Metab 2:129-145